CLINICAL RESULTS OF BIOSLIFE
Clinical Results Of Bioslife Lowering LDL Cholesterol And Increasing HDL Cholesterol
Lower Cholesterol
BiosLife Complete
"Dangerous cholesterol levels dropped 52% in some of our study's participants!"
Dr. Peter Verdegem,
Unicity Chief Science Officer
Unicity Chief Science Officer
LOWERING LDL CHOLESTEROL AND INCREASING HDL CHOLESTEROL - CLINICAL RESULTS OF BIOSLIFE
Clinical Results
Only BiosLife offers complete cholesterol care in lowering LDL cholesterol and increasing HDL cholesterol.
Extensive clinical testing has proven beyond all expectations that BiosLife is a major breakthrough in lowering LDL cholesterol and increasing HDL cholesterol levels.
These studies show that BiosLife lowers LDL cholesterol or “bad” cholesterol for participants with high LDL levels by an astounding 31%. Some participants reported decreases of up to 50%.
What is equally amazing is that the average increase of HDL cholesterol or “good” cholesterol in those participants with low HDL levels was 29%, with some achieving increases of up to 85%!
Now for a surprise: if you’re already treating your cholesterol levels with a prescription, BiosLife will help you by lowering LDL cholesterol even further.
The truth is, in addition to improving LDL and HDL levels, BiosLife lowers triglycerides- the form in which most fat exists in food as well as in your body and blood. BiosLife also has proven to stabilize blood sugar levels. No other supplement is more comprehensive for treating your entire lipid profile than BiosLife.
In a double-bind, placebo-controlled study conducted at the highly respected Cleveland Clinic, BiosLife was clinically proven to lower LDL cholesterol and triglyceride levels.
ADDITIONAL INFORMATION
Additional Information
Dennis L. Sprecher M.D. from the prestigious Cleveland Clinic Institute states that Bios Life 2 should be used for primary prevention of hypercholestremia.
One of our most important recommended formulations was proven safe and effective by the renowned Cleveland Clinic in a double blind, placebo-controlled, randomized study.
Results Presented on Cleveland Clinic Trial on BiosLife 2®
Below is the published (after peer review) abstract of the Cleveland Clinic Trial on BiosLife 2 that has been recorded in the Official Abstract Book for International Academy of Cardiology in Washington, D.C. (attended by Dr. Dennis Sprecher from the Cleveland Clinic, who oversaw the study).
Dr. Sprecher presented the results of this study at the 2nd INTERNATIONAL CONGRESS ON HEART DISEASE - NEW TRENDS IN RESEARCH, DIAGNOSIS AND TREATMENT, held in Washington, DC, July 21 to 24, 2001 under the auspices of:
1. INTERNATIONAL ACADEMY OF CARDIOLOGY
2. INTERNATIONAL SOCIETY OF HEART FAILURE
(Also included at the end is a layman's explanation of the abstract from Rik Deitsch, Biochemist and Director of Science & Education for Unicity Network)
Dennis L. Sprecher M.D. from the prestigious Cleveland Clinic Institute states that Bios Life 2 should be used for primary prevention of hypercholestremia.
One of our most important recommended formulations was proven safe and effective by the renowned Cleveland Clinic in a double blind, placebo-controlled, randomized study.
Results Presented on Cleveland Clinic Trial on BiosLife 2®
Below is the published (after peer review) abstract of the Cleveland Clinic Trial on BiosLife 2 that has been recorded in the Official Abstract Book for International Academy of Cardiology in Washington, D.C. (attended by Dr. Dennis Sprecher from the Cleveland Clinic, who oversaw the study).
Dr. Sprecher presented the results of this study at the 2nd INTERNATIONAL CONGRESS ON HEART DISEASE - NEW TRENDS IN RESEARCH, DIAGNOSIS AND TREATMENT, held in Washington, DC, July 21 to 24, 2001 under the auspices of:
1. INTERNATIONAL ACADEMY OF CARDIOLOGY
2. INTERNATIONAL SOCIETY OF HEART FAILURE
(Also included at the end is a layman's explanation of the abstract from Rik Deitsch, Biochemist and Director of Science & Education for Unicity Network)
ABSTRACT
FIBER-MULTIVITAMIN BLEND:
AN OVER-THE-COUNTER LDL LOWERING PRODUCT
AN OVER-THE-COUNTER LDL LOWERING PRODUCT
Dennis L. Sprecher, MD,1 Gregory L. Pearce,1 Anita M.Boddie, RD, PhD,2 Nader Fotouhi, PhD,2 Vicki Horiatis, RN,1
1 The Cleveland Clinic Foundation, Cleveland, Ohio
2 Rexall Sundown, Inc., Boca Raton, Florida
Background:
A commonly used 90% soluble fiber-blend product (BiosLife 2) has not been evaluated for lipid altering effect. Few data are available to describe the influence of fiber on serum ApoB levels. Further, as a fiber-vitamin combination agent, the potential claim of folate/B6 benefit in the setting of fiber intake has not been examined.
Methods:
Patients (n=119) were randomized to either a fiber blend treatment, or placebo with 99 (50 treatment, 49 placebo) completing the study. Fasting lipid profiles (including ApoB), and homocysteine concentrations were obtained at weeks 4 and 8. Between group (Wilcoxon rank-sums test) and within group (paired t-tests) comparisons were used to evaluate treatment effect.
Results:
Subjects in both groups showed similar baseline LDL levels (159mg/dl vs. 158mg/dl). The treatment group showed a 7.9% +/- 11.0 reduction (p<0.001) over 8 weeks. Placebo patients showed a slight increase in LDL over the same period (+2.4% +/- 11.7, p=0.16), for a 10.3% difference between groups (p<0.001). ApoB measured in a subset (n=53) revealed a 20% reduction with treatment (p=0.004). Treatment subjects showed a reduction in homocysteine (9.8 mg/dl to 8.7 mg/dl, p=0.02), while neither TG (p=0.95) nor HDL-c (p=0.54) changed.
Conclusions:
Significant LDL and ApoB lowering effects are demonstrated. No adverse effects on triglyceride or HDL cholesterol levels were noted, and folate/B vitamin derived benefits towards homocysteine reduction were preserved. This combination product could be used to reduce the need for concomitant lipid lowering prescription therapy, as well as for advancing self-styled primary prevention strategies.
BIOSLIFE 2 - ABSTRACT EXPLANATION
BiosLife 2 - Abstract explanation
Before medications are approved for widespread use, they are typically tested in a controlled clinical trial. Controlled trials are considered necessary to show that a medication's effects are not subjective (relying on the patient's or physician's interpretation). Otherwise, a researcher might (perhaps unintentionally) test the medication only in patients who already show signs of responding well to treatment. Or a patient, knowing that the medication is supposed to have a specific effect, could experience that effect due to some other factor, but attribute the relief solely to the new medication.
The preferred way to avoid subjectivity is to do a controlled study. In a controlled study, or trial, patients in one group receive the investigational product; while patients in another group-the control group-receive a placebo (an inactive substance that is indistinguishable from the investigational product). This arrangement allows researchers to compare the health of the group receiving the new product with the control group. If the group receiving the new product shows clear and measurable improvements in symptoms, but the control group does not, researchers can reasonably conclude that the new product was responsible for improving the health of the treatment group.
To ensure that comparisons between a treatment group and control group are scientifically valid, researchers select people for both groups who are similar in age, weight, health status, and other factors. The most common way to accomplish this is through randomization. Researchers first gather a group of people with similar characteristics. They then randomly assign each person to either the treatment group or the control group. This ensures that certain patients aren't "hand picked" for a group because of their characteristics.
The final step in ensuring that a research study is objective is blinding. Blinding is used to eliminate the effects of personal beliefs and biases (on the part of both researchers and patients). In a single-blind study, the patients do not know whether they are in the treatment group or the control group, but the researchers do know. In a double-blind study, no one involved-not the patients, researchers, or data analysts-know which patients are receiving the new product and which are not.
A controlled, randomized, double-blind clinical trial therefore produces the most objective and scientifically valid results.
The abstract explains the results of the controlled, randomized, double-blind clinical trial on the BiosLife 2 that was accomplished by the Cleveland Clinic.
The abstract states that 119 patients were randomized for the trial. All of the patients were required to eat the same low fat diet for the six weeks leading up to the trial and then continue on a controlled diet throughout the trial. This isolated the variable. In other words, the patients' diet would not have been the cause of any difference in serum cholesterol as all of the patients had been following the same diet.
Ninety-nine patients completed the trial (50 on the BiosLife 2 and 49 on the placebo). Blood work was done at the fourth and the eighth week of the trial. The values obtained from the blood work were then statistically analyzed. Accepted methods of mathematical analysis can determine whether a difference in treatment outcomes is statistically significant. A statistically significant difference means that the result is very unlikely to be due to chance alone. Researchers represent the degree of certainty in a result as what is called a "p value." A p value of less than 0.05 indicates that the results of the study are statistically accurate and did not occur by chance. Achieving a significant p value is heavily dependent on the number of people in the groups that are being compared.
LDL is "Low Density Lipoprotein". A lipoprotein substance (combination of a fat and a protein) acts as a carrier for cholesterol and fats in the bloodstream. High levels of low density lipoprotein (LDL) cholesterol are considered a positive risk factor for the development of coronary artery disease. Less than 130 mg/dl is desirable, 130 to 159 mg/dl is borderline high, over 160 is considered high. The results showed that there was an average difference in LDL cholesterol levels of 10.3% between the groups. This is statistically significant (p<0.001) and shows the difference being solely attributable to the BiosLife 2.
ApoB is "Apolipoprotein B". Apolipoproteins are proteins on the surface of the lipoprotein complex that bind to specific enzymes or transport proteins on the cell membranes; this directs the lipoprotein to the proper site of metabolism. ApoB is in LDL (low density lipoprotein). Unlike HDL and LDL cholesterol measurements (which are indirect), apolipoprotein levels can be measured directly. Knowing a patient's ApoB levels may give a much more accurate picture of their health, including the risk for heart disease. The results showed a 20% reduction in ApoB with treatment. This value showed statistical significance (p=0.004).
Homocysteine is an amino acid produced by the body by altering another amino acid, methionine. In a healthy system, homocysteine is usually converted into other amino acids. Elevated levels of homocysteine in the blood appear to make for an elevated risk of cardiovascular (heart and vessel) disease. Homocysteine can damage blood vessels in several ways. It injures the cells that line arteries and stimulates the growth of smooth muscle cells. Homocysteine can also disrupt normal blood clotting mechanisms, increasing the risk of clots that can bring on a heart attack or stroke. The results showed an 11.2% reduction in homocysteine levels in the patients taking Bios Life 2. This value has lower statistical significance (p=0.02) and the changes cannot be wholly attributed to the product.
TG represents "triglycerides". These are the storage units for fat in the body. Elevations of the triglyceride level (particularly in association with elevated cholesterol) have been correlated with the development of atherosclerosis, an underlying cause of heart disease and stroke. The results showed a reduction in triglycerides that was not statistically significant (p=0.95). As such, the article will represent that "triglycerides were unchanged". Even that is important as many other methods for lowering serum cholesterol may increase triglyceride levels.
HDL is "High Density Lipoprotein". Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease). The results showed an increase in HDL cholesterol that was not statistically significant (p=0.54). As such, the article will represent that "HDL levels were unchanged". Again, even that is important as many other methods for lowering serum cholesterol may decrease HDL cholesterol levels.
The most encouraging part of the abstract lies in the conclusion. Almost every study that is completed on complementary therapies states an ambiguity in the conclusion. Usually something to the effect of "These results suggest that more study is warranted." Dr. Sprecher never states anything like that. His simple conclusion is that the BiosLife 2 was effective in the clinical trial. He even states that BiosLife 2 should be used for primary prevention of hypercholestremia.
One more thing, BiosLife’s only side effect is weight loss.
More clinical results on Bioslife: Utah Trial
You can also visit:
Bioslife Testimonials to read about the many people who have benefitted from BiosLife™ Complete lowering their LDL cholesterol and increasing their HDL cholesterol levels.
Bioslife FAQs for the Frequently Asked Questions about BiosLife™ Complete in lowering LDL cholesterol levels.
Lowering LDL Cholesterol With Bioslife for more information on how to start using BiosLife™ Complete to lower your LDL cholesterol and bring about other health benefits.
Back to Lowering Cholesterol Levels Home Page
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. The information and claims made in this site have not been evaluated by the United States Food and Drug Administration and are not approved to diagnose, treat, cure or prevent disease.